Meet Neuland at CPHI India 2026 | Hall 2, Booth 2D38 | Yashobhoomi Convention Centre, New Delhi | 24-26 November 2026 Schedule a Meeting
Meet Neuland at CPHI India 2026 | Hall 2, Booth 2D38 | Yashobhoomi Convention Centre, New Delhi | 24-26 November 2026 Schedule a Meeting
Pharmaceutical companies rely on consistent and predictable supply of active pharmaceutical ingredients (APIs) to meet stringent regulatory, quality, and production timelines. Any disruptions—whether due to natural disasters, supply chain bottlenecks, regulatory issues, or cyber threats—can lead to production delays, raw material constraints, increased costs due to emergency sourcing, reputational risks, and in the worst-case scenario, shortages of critical medicines that patients rely on.
To mitigate these risks, sponsors audit suppliers for concerns like quality and on-time performance. For true security of supply, however, sponsors should widen this lens to consider a broader concern: business continuity. Working with an API supplier with a well-developed business continuity management system (BCMS) plan provides the greater level of assurance that pharmaceutical sponsors need.
Your API provider’s business continuity planning is critical for ensuring your reliable supply of high-quality product. The provider’s BCMS protects you in five key ways:
A robust BCMS is designed to prevent disruptions in the production and shipment of APIs, ensuring that customers receive on-time deliveries, to keep drug product manufacturing on schedule. The API manufacturer’s redundancy planning and backup production capabilities provide customers with reliable inventory planning, reducing last-minute procurement issues.
A disruption in the raw material supply chain can impact active pharmaceutical ingredients production. Through a strong risk management framework, an API manufacturer develops a diversified supplier base for critical raw materials, identifying and mitigate potential bottlenecks and reducing dependency on single sources. These redundant inventory strategies buffer against delays and geopolitical uncertainties.
A BCMS includes a crisis management team, which develops and implements rapid response mechanisms, including simulations and stress tests to validate emergency response capabilities. The team also ensures continuous customer communication and transparency in the event of any potential delay.
With increasing digitization, cyber threats pose a major risk to API manufacturers and their customers. A robust IT disaster recovery plan and cybersecurity protocols protect sensitive customer data and ensure resilience against cyber-attacks. These measures prevent operational downtime, securing uninterrupted access to production, compliance, and logistics systems.
Intellectual property (IP) is also often an overlooked aspect of pharmaceuticals, especially in API manufacturing. A CDMO with IP expertise supports companies by identifying opportunities to expand while simultaneously reducing risks and roadblocks.
An API supplier with a robust BCMS provides customers with the peace of mind of predictable and stable API procurement, leading to improved supply chain planning. This assurance also lower regulatory risks, as a compliance-driven BCMS minimizes disruptions. Ensuring continuous patient access to essential medicines also enhances the customer’s market reputation.
Knowing the criticality of providing a reliable supply of high-quality active pharmaceutical ingredients, Neuland has invested the time and resources to develop a robust business continuity management system. This process involved three main steps, conducting a business impact analysis, brainstorming risks, and carrying out real-world simulations.
Developing the BCMS was not the end of the process, however, because a BCMS cannot remain static. The company continues to conduct comprehensive crisis response drills, including fire, supply chain disruptions, and cybersecurity incidents. Ongoing supply chain testing, in turn, ensures active pharmaceutical ingredient availability under stress conditions. Risk assessments are regularly updated. Underlying these efforts is the company’s commitment to continuous improvements to its processes and redundancy planning. This work will ultimately culminate in ISO 22301:2019 certification to demonstrate the organization’s global best practices.
When choosing an API supplier, a pharmaceutical company needs to look beyond typical supply chain audits to consider the broader concern of business continuity management. An API manufacturer with a well-developed BCMS provides five key benefits to customers: uninterrupted API supply, supply chain resilience through alternative sourcing, proactive crisis management, strong cybersecurity and data protection, and competitive advantage.
Neuland developed its BCMS through three essential steps: a comprehensive business impact analysis to identify critical operations, collaborative risk brainstorming across departments, and real-world simulation exercises to test response strategies. The company continues to strengthen its system through regular crisis response drills, supply chain testing, and updated risk assessments, ensuring that the BCMS is a dynamic system, always at the ready.
Neuland Laboratories’ business continuity management system is not just an internal safeguard; it is a strategic commitment to customers. By proactively identifying risks, ensuring supply chain resilience, and maintaining regulatory compliance, Neuland provides unmatched reliability, quality assurance, and operational transparency, with on-time delivery performance exceeding industry standards. Through proactive planning and risk management, Neuland allows customers to focus on their core business with confidence, knowing they have a trusted and resilient API partner.
